Abstract
714P - Phase I study of the oncolytic viral immunotherapy agent canerpaturev (C-REV) with S-1 in patients with stage IV pancreatic cancer
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have